Increased markers of inflammation and endothelial dysfunction in patients with mild primary hyperparathyroidism

References

• Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart Disease – a review. Eur Heart J 2004;25:1776–87.
   PubMed Web of Science ®Google Scholar
• Almqvist EG, Bondeson AG, Bondeson L, Nissborg A, Smedgård P, Svensson SE. Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy. Surgery 2002;132:1126–32.
   PubMedGoogle Scholar
• Almqvist EG, Becker C, Bondeson AG, Bondeson L, Svensson J, Svensson SE. Increased plasma concentrations of N-terminal pro-B-type natriuretic peptide in patients with mild primary hyperparathyroidism. Clin Endocrinol (Oxf) 2006;65:760–6.
   PubMedGoogle Scholar
• Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem 2009;55:229–38.
   PubMed Web of Science ®Google Scholar
• Abeywardena MY, Leifert WR, Warnes KE, Varghese JN, Head RJ. Cardiovascular biology of interleukin-6. Curr Pharm Des 2009;15:1809–21.
   PubMed Web of Science ®Google Scholar
• Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009;78:539–52.
   PubMed Web of Science ®Google Scholar
• Roldán V, Marín F, Lip GY, Blann AD. Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost 2003;90:1007–20.
   PubMed Web of Science ®Google Scholar
• Grey A, Mitnick MA, Shapses S, Ellison A, Gundberg C, Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption – a clinical research center study. J Clin Endocrinol Metab 1996;81:3450–4.
   PubMed Web of Science ®Google Scholar
• Halabe A, Shohat B. Effect of parathyroid adenoma excision on interleukin-6 (IL-6) and IL-2 receptor levels. Metabolism 2000;49:192–4.
   Google Scholar
• Guo CY, Holland PA, Jackson BF, Hannon RA, Rogers A, Harrison BJ, Eastell R. Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism. Eur J Endocrinol 2000;142:451–9.
   PubMed Web of Science ®Google Scholar
• Ogard CG, Engelmann MD, Kistorp C, Nielsen SL, Vestergaard H. Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf) 2005;63:493–8.
   PubMedGoogle Scholar
• Chertok-Shacham E, Ishay A, Lavi I, Luboshitzky R. Biomarkers of hypercoagulability and inflammation in primary hyperparathyroidism. Med Sci Monit 2008;14:CR628–32.
   Google Scholar
• Luboshitzky R, Chertok-Schaham Y, Lavi I, Ishay A. Cardiovascular risk factors in primary hyperparathyroidism. J Endocrinol Invest 2009;32:317–21.
   PubMed Web of Science ®Google Scholar
• Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K. Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2002;87:4946–51.
   Google Scholar
• Safley SA, Villinger F, Jackson EH, Tucker-Burden C, Cohen C, Weber CJ. Interleukin-6 production and secretion by human parathyroids. Clin Exp Immunol 2004;136:145–56.
   Google Scholar
• Bollerslev J, Rosen T, Mollerup CL, Nordenström J, Baranowski M, Franco C, Pernow Y, Isaksen GA, Godang K, Ueland T, Jansson S; SIPH Study Group. Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2009;94:2255–61.
   PubMed Web of Science ®Google Scholar
• Cruickshank AM, Fraser WD, Burns HJ, Van Damme J, Shenkin A. Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci (Lond) 1990;79:161–5.
   PubMed Web of Science ®Google Scholar
• Reppe S, Stilgren L, Abrahamsen B, Olstad OK, Cero F, Brixen K, Nissen-Meyer LS, Gautvik KM. Abnormal muscle and hematopoietic gene expression may be important for clinical morbidity in primary hyperparathyroidism. Am J Physiol Endocrinol Metab 2007;292:E1465–73.
   Google Scholar
• Seeliger S, Hausberg M, Eue I, Usdin T, Rahn KH, Kosch M. The parathyroid hormone-2 receptor is expressed on human leukocytes and down-regulated in hyperparathyroidism. Clin Nephrol 2003;59:429–35.
   Google Scholar
• Kotzmann H, Köller M, Abela C, Clodi M, Riedl M, Graninger W, Niederle B, Luger A. Effects of parathyroid hormone and serum calcium on the phenotype and function of mononuclear cells in patients with primary hyperparathyroidism. Eur J Clin Invest 1998;28:353–8.
   Google Scholar
• Ahmad S, Otaal PS, Rai TS, Bahl A, Saikia UN, Manoj RK, Thungapathra M, Talwar KK, Khullar M. Circulating proinflammatory cytokines and N-terminal pro-brain natriuretic peptide significantly decrease with recovery of left ventricular function in patients with dilated cardiomyopathy. Mol Cell Biochem 2009;324:139–45.
   PubMed Web of Science ®Google Scholar
• Bahrami H, Bluemke DA, Kronmal R, Bertoni AG, Lloyd-Jones DM, Shahar E, Szklo M, Lima JA. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008;51:1775–83.
   PubMed Web of Science ®Google Scholar
• Abdu TA, Elhadd T, Pfeifer M, Clayton RN. Endothelial dysfunction in endocrine disease. Trends Endocrinol Metab 2001;12:257–65.
   PubMed Web of Science ®Google Scholar